IBAB Ion Beam Applications SA

IBA and Apollo Hospitals sign a term sheet for one Proteus®ONE system plus a second one in option to be installed in India

IBA and Apollo Hospitals sign a term sheet for one Proteus®ONE system plus a second one in option to be installed in India


Louvain-La-Neuve, Belgium, March 04, 2025 – (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a term sheet with Apollo Hospitals Enterprise Limited (AHEL) for the supply of one Proteus®ONE1 compact proton therapy solution plus a second one in option. Apollo will therefore expand access to proton therapy in India. The term sheet was signed in the presence of Her Royal Highness Princess Astrid of Belgium.

These systems expand upon the existing collaboration between the two partners, with AHEL having previously selected an IBA Proteus®PLUS1 system in 2013 and introduced the first proton beam therapy in India. AHEL expects to start treating patients with the Proteus®ONE systems by 2028.

Proteus®ONE is the market leading compact proton therapy system, which is upgradable over time to continue providing the latest technology to IBA users. The systems will include DynamicARC®2 beam delivery capabilities when regulatory clearance is granted.

The typical end-user price for a Proteus®ONE system with a multi-year maintenance contract ranges between EUR 35 and 45 million.

Olivier Legrain, Chief Executive Officer of IBA, commented: “These contracts expand upon the close relationship we have built for more than a decade with Apollo Hospitals. Having an existing customer reaffirm their confidence in our solutions demonstrates not only the reliability and superiority of the IBA portfolio but also highlights the level of excellence of the services we deliver. We look forward to further strengthening our relationship with Apollo as we enable more patients in India to gain access to this life-saving treatment modality.”

Dr. Prathap C Reddy, Founder and Chairman of Apollo Hospitals Enterprise Ltd, added: Our relentless pursuit of excellence in healthcare drives us to bring the most advanced medical technologies to India. In 2019, Apollo commissioned the first proton therapy system in India and till date we have treated over 2000 patients from over 147 countries. We are excited to partner with IBA again as we expand our proton therapy treatment capacity. The addition of Proteus®ONE further cements our position as a global leader in proton beam therapy treatments, enabling us to deliver superior clinical outcomes and improve the quality of life for cancer patients in India and worldwide.”

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered to be the most advanced form of radiation therapy available today, industrial sterilization, radiopharmaceuticals, and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,000 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at:

About Apollo Hospitals Entreprise Limited

Apollo Hospitals Enterprise Ltd (AHEL) revolutionised healthcare when Dr. Prathap C. Reddy opened the first hospital in Chennai in 1983. Today, AHEL is India’s largest integrated healthcare platform with over 10,000 beds across 73 hospitals, over 6000 pharmacies and over 200 clinics and diagnostic centres, as well as 150 telemedicine centres. It is the world’s leading Cardiac Centre with over 200,000 surgeries and the world’s largest private cancer care provider. Apollo continues to invest in research to bring the most cutting-edge technologies, equipment and treatment protocols to ensure patients have the best available care in the world. Apollo’s 100,000 family members are dedicated to bringing the best care making a better world.

CONTACTS

IBA

Olivier Lechien

Corporate Communication Director



ICR Healthcare

Amber Fennell, Angela Gray, Lucy Featherstone

+44 (0) 20 3709 5700





1 Proteus®ONE and Proteus®PLUS are the brand names of Proteus®235.

2 DynamicARC® is a registered brand of the IBA’s Proton Arc therapy solution currently under development phase.



Attachment



EN
04/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ion Beam Applications SA

 PRESS RELEASE

IBA – TRANSPARENCY NOTIFICATION

IBA – TRANSPARENCY NOTIFICATION (Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, February 25, 2026 06:00 PM Summary of the notification IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on February 13, 2026. In its notification, Premier Miton Group plc indi...

 PRESS RELEASE

IBA SA – NOTIFICATION TRANSPARENCE

IBA SA – NOTIFICATION TRANSPARENCE (article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes) Louvain-la-Neuve, Belgique, le 25 février 2026, 18:00 Résumé de la notification IBA (Ion Beam Applications SA), le premier fournisseur mondial de solutions de protonthérapie pour le traitement du cancer, annonce devoir effectuer une notification en matière de transparence conformément à l'article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes (« loi transparence »), à la suite d’une notification reçue le ...

 PRESS RELEASE

IBA – ACQUISITION OF OWN SHARES

IBA – ACQUISITION OF OWN SHARES Louvain-la-Neuve, Belgium, February 23rd, 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on February 2nd, 2026. Under this program, IBA has requested a financial intermediary to repurchase up to 400,000 IBA ordinary shares on its behalf under the terms of a mandate with validity until September 30th, 2026 (included), effective as from February 3rd, 20...

 PRESS RELEASE

IBA – ACQUISITION D’ACTIONS PROPRES

IBA – ACQUISITION D’ACTIONS PROPRES Louvain-la-Neuve, Belgique, 23 février 2026 – 18h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") communique par la présente certaines informations relatives à son programme de rachat d'actions annoncé le 2 février 2026. Dans le cadre de ce programme, IBA a demandé à un intermédiaire financier de racheter en son nom un maximum de 400.000 actions ordinaires IBA selon les termes d'un mandat valable jusqu'au 30 septembre 2026 et effectif à part...

Guy Sips ... (+9)
  • Guy Sips
  • Hilde Van Boxstael
  • Kristof Samoy
  • Mathijs Geerts Danau
  • Michiel Declercq
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi

Morning Notes : ABI BB, AGN NA, ARCAD NA, BESI NA, ENX FP, GIMB BB, HY...

: ABI BB, AGN NA, ARCAD NA, BESI NA, ENX FP, GIMB BB, HYL BB, IBAB BB, KIN BB, MTLS US, VGP BB, AZE BB, ZEAL DC

ResearchPool Subscriptions

Get the most out of your insights

Get in touch